Akeso Biomedical™ Closes Financing Round of $4.4M
Akeso will use some of the funds to develop manufacturing and global distribution partnerships for TYPLEX™ Chelate, a zootechnical gut health stabilizer which inhibits pathogenic bacteria, such as Clostridium, Campylobacter, Salmonella and E. coli from adhering to avian gut walls. Use of TYPLEX Chelate as a feed additive has been shown in trials to result in an improved gut microbiome in broilers, allowing better nutrient absorption and leading to better performance in the grow-out of chickens, without the use of antibiotics.
In addition, Akeso is pursuing other applications of its Fe3C technology in animal health, including improvements in weaner piglet health, welfare, performance and gut microflora. The funds will also allow the company to progress those initiatives.
Simon Williams, CEO of Akeso Biomedical, said, “We are pleased with the continuing commitment from our existing investors and welcome the new investors in this latest round. We are eager to bring our TYPLEX™ Chelate to market with a strong commercial partner and begin to grow the product categories.”
About Akeso Biomedical, Inc.
Akeso Biomedical, Inc. is an animal health and food safety company developing new solutions to improve animal welfare and performance and to prevent foodborne illnesses. Akeso uses a proprietary broad-spectrum iron chelate chemistry known as Fe3C. The Company’s product pipeline includes Fe3C feed additives designed to improve intestinal health and nutrient absorption in food animals, by reducing carriage of enteropathogens, including Salmonella, Campylobacter, Clostridium, and E. coli, among others. For more information please send inquiries to [email protected].
Akeso Biomedical, Inc. is a VIC Technology Venture Development™ portfolio company.
ContactsAkeso Biomedical, Inc.
&source=" target="_blank" />
Jerome Meier, 860-833-3858
Chief Operating Officer
[email protected]
Funding for the Commercial Launch of Feed Additives for Poultry
and Piglets to Combat Foodborne Illnesses and Improve Animal Microbiomes
WALTHAM, Mass.–(BUSINESS WIRE)–Akeso Biomedical, Inc., announced today that it closed its most recent
financing of $4.4M from existing and new investors. Akeso Biomedical is
a privately held company developing novel, non-antibiotic feed additive
technologies to improve food safety, animal health and production.
Akeso’s feed additives inhibit colonization of animal hosts by bacterial
pathogens, thereby reducing the risk of foodborne illness and improving
animal performance and value on the farm.
Akeso will use some of the funds to develop manufacturing and global
distribution partnerships for TYPLEX™ Chelate, a zootechnical gut health
stabilizer which inhibits pathogenic bacteria, such as Clostridium,
Campylobacter, Salmonella and E. coli from adhering to avian gut
walls. Use of TYPLEX Chelate as a feed additive has been shown in trials
to result in an improved gut microbiome in broilers, allowing better
nutrient absorption and leading to better performance in the grow-out of
chickens, without the use of antibiotics.
In addition, Akeso is pursuing other applications of its Fe3C technology
in animal health, including improvements in weaner piglet health,
welfare, performance and gut microflora. The funds will also allow the
company to progress those initiatives.
Simon Williams, CEO of Akeso Biomedical, said, “We are pleased with the
continuing commitment from our existing investors and welcome the new
investors in this latest round. We are eager to bring our TYPLEX™
Chelate to market with a strong commercial partner and begin to grow the
product categories.”
About Akeso Biomedical, Inc.
Akeso Biomedical, Inc. is an animal health and food safety company
developing new solutions to improve animal welfare and performance and
to prevent foodborne illnesses. Akeso uses a proprietary
broad-spectrum iron chelate chemistry known as Fe3C. The Company’s
product pipeline includes Fe3C feed additives designed to improve
intestinal health and nutrient absorption in food animals, by reducing
carriage of enteropathogens, including Salmonella, Campylobacter,
Clostridium, and E. coli, among others. For more information please send
inquiries to [email protected].
Akeso Biomedical, Inc. is a VIC
Technology Venture Development™ portfolio company.
Contacts
Akeso Biomedical, Inc.
Jerome Meier, 860-833-3858
Chief
Operating Officer
[email protected]
